GT
GTN.F Getinge AB
- Market cap
- EUR 6.83B
- P/E
- 26.4x
- P/B
- 2.26x
- ROE
- 8.0%
- Dividend yield
- 1.78%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GTN.F undervalued?
Graham numberGTN.F trades 63.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Getinge AB fundamental analysis
No fundamental analysis for Getinge AB yet.
Getinge AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Getinge AB
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel h…
Full company profileGetinge AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Getinge AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 29.8B | 22.5B | 24.2B | 26.6B | 29.8B | 27.0B | 28.3B | 31.8B | 34.8B | 35.0B | 32.4B |
| Gross Profit | 13.8B | 10.6B | 11.1B | 12.5B | 14.7B | 13.6B | 13.4B | 14.5B | 16.2B | 16.7B | 16.2B |
| Operating Income | 3.62B | 2.26B | -284M | 2.70B | 4.96B | 4.27B | 3.88B | 3.69B | 3.70B | 4.46B | 4.36B |
| EBITDA | - | 4.05B | 1.60B | 4.55B | 7.20B | 6.15B | 5.70B | 5.91B | 5.31B | 6.06B | 6.39B |
| Net Income | 1.19B | 1.38B | -967M | 1.22B | 3.24B | 2.97B | 2.49B | 2.41B | 1.64B | 2.26B | 2.61B |
| EPS | - | 5.05 | -3.55 | 4.49 | 12 | 11 | 9.15 | 8.86 | 6.01 | 8.29 | 9.60 |
| Balance Sheet | |||||||||||
| Total Assets | 55.2B | 42.1B | 43.4B | 44.7B | 45.0B | 44.6B | 52.0B | 53.6B | 63.9B | 56.5B | 59.6B |
| Total Liabilities | 34.3B | 22.3B | 23.7B | 23.7B | 23.5B | 19.4B | 21.6B | 23.2B | 30.7B | 27.0B | 26.9B |
| Shareholders' Equity | 20.5B | 19.4B | 19.2B | 20.5B | 21.0B | 24.7B | 30.0B | 30.2B | 33.0B | 29.4B | 32.7B |
| Cash & Short-term Investments | 1.68B | 1.53B | 1.27B | 1.25B | 6.06B | 4.08B | 5.68B | 2.73B | 2.96B | 3.40B | 3.16B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.67B | 2.76B | 2.50B | 3.83B | 7.20B | 6.56B | 3.37B | 2.65B | 4.58B | 3.95B | 5.29B |
| Capital Expenditure | 1.43B | 811M | 555M | 385M | 437M | 462M | 1.14B | 1.33B | 1.31B | 1.31B | 1.11B |
| Free Cash Flow | - | 1.10B | 1.12B | 2.61B | 6.15B | 5.63B | 2.23B | 1.32B | 3.27B | 2.64B | 4.18B |
| Ratios | |||||||||||
| ROE | 5.8% | 7.1% | -5.0% | 6.0% | 15.4% | 12.0% | 8.3% | 8.0% | 5.0% | 7.7% | 8.0% |
| ROA | 2.2% | 3.3% | -2.2% | 2.7% | 7.2% | 6.7% | 4.8% | 4.5% | 2.6% | 4.0% | 4.4% |
| Net Profit Margin | 4.0% | 6.1% | -4.0% | 4.6% | 10.9% | 11.0% | 8.8% | 7.6% | 4.7% | 6.5% | 8.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Getinge AB dividends
- Dividend yield
- 1.78%
- Forward dividend
- 0.44 EUR
- Payout ratio
- 56.1%
- Ex-dividend date
- Apr 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | SEK 1.27B | 4.65 | 56.1% |
| 2024 | SEK 1.23B | 4.50 | 74.9% |
| 2023 | SEK 1.18B | 4.34 | 49.0% |
| 2022 | SEK 1.11B | 4.08 | 44.6% |
| 2021 | SEK 817M | 3.00 | 27.5% |
| 2020 | SEK 409M | 1.50 | 12.6% |
| 2019 | SEK 272M | 1.00 | 22.3% |
| 2018 | SEK 409M | 1.50 | - |
| 2017 | SEK 477M | 1.75 | 34.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Nov 27, 2003.
Who owns Getinge AB
- Insiders 15.20%
- Institutions 62.41%
- Public & others 22.39%
- Shares outstanding 254M
- Free float 179M
Getinge AB company profile
- Company name
- Getinge AB
- Ticker
- GTN.F
- ISIN
- SE0000202624
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 11,847
- Fiscal year end
- December
- Address
- Lindholmspiren 7A, Gothenburg, Sweden, 417 56
- Phone
- 46 1 03 35 00 00
- Website
- getinge.com
About Getinge AB
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardiothoracic surgery equipment, peripheral stenting, OEM solutions, and beating heart surgery equipment; and operating room equipment, anesthesia, advanced patient monitoring, and operating room integration solutions. Further, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices, and patient flow management; and low temperature sterilization, biocontainment in vaccine production, terminal sterilization, sterile isolation technology, cleaning and sterilization, aseptic transfer, and large-scale cultivation. Additionally, the company provides bioreactor preparation solution, bioprocess development and optimization, labware cleaning and sterilization, biocontainment, and vivarium. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.
Getinge AB management
10- Mr. Mattias Perjos M.Sc.CEO, President & Director · born 1972
- Ms. Agneta PalmerChief Financial Officer · born 1978
- David KordelHead of Investor Relations
- Ms. Anna Romberg MSc EconExecutive Vice President of Sustainability, Legal & Compliance · born 1979
- Ms. Alexandra HollandExecutive Vice President of Brand & Communications · born 1986
- Mr. Magnus Lundback Ph.D.Executive Vice President of Human Resources · born 1969
- Mr. Carsten BleckerChief Commercial Officer · born 1966
- Mr. Stephane Le RoyPresident of Surgical Workflows · born 1977
- Ms. Patricia A. FitchPresident of North America Region
- Ms. Elin Frostehav M.Sc.President of Acute Care Therapies · born 1982